|02/12/18||Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results|
|AUSTIN, Texas, Feb. 12, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2017. Financial and operating highlights for the quarter and full-year include:
Fourth quarter and full-year 2017 consolidated revenue was $78.2 million and $306.6 million, an increase of 8% and 13%, respectively, compared to the fourth quarter and full-year 2016.
Assay revenue was $41.8 million and $154.9 million for the quarter and ... |
|02/06/18||Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference|
|AUSTIN, Texas, Feb. 6, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7th Annual Global Healthcare Conference to be held February 14-15, 2018, in New York, NY.
The investor presentation will begin at 10:30 a.m. Eastern time on Thursday, February 15, 2018. The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address ... |
|01/24/18||Luminex Corporation Declares First Quarter Cash Dividend|
|AUSTIN, Texas, Jan. 24, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of 2018 of $0.06 per share of common stock payable on April 13, 2018 to stockholders of record as of the close of business on March 23, 2018.
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide ... |
|01/07/18||Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference|
|AUSTIN, Texas, Jan. 7, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2017 to be approximately $78 million and to exceed $306 million for the full- year ended 2017. These expected results reflect increases of 8% and 13% compared to the respective periods in 2016.
Select fourth quarter highlights include:
Total MDx revenue of approximately $44 million, grew 12% over the fourth quarter of 2016
The MDx s... |